Thus, CD19-CAR T cell efficacy is also correlated with antigen-independent cytotoxicity [53], and the complexity of genomic and epigenomic alterations in lymphoma cells needs to be further analyzed to understand the alternative mechanisms of resistance to CD19-CAR T cell therapy. The gene discussed is CD19; the disease is lymphoma.